(lp0
S'Cytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results GlobeNewswire  - Feb 16, 2017 16, 2017  -- Cytokinetics, Inc.  reported total revenues for the fourth quarter of 2016 were $33.1 million, compared to $9.8 million, during the same period in 2015.Cantor Fitzgerald Releases a Buy Rating on Cytokinetics Inc - Analyst RatingsPiper Jaffray Reiterates Overweight Rating and $15 PT on Cytokinetics (CYTK ... - StreetInsider.com'
p1
aS"Why Cytokinetics, Inc. Got Hammered Today Motley Fool - Sep 1, 2016 What happened. Cytokinetics  is down 13% heading into the closing bell Thursday after announcing plans to start a phase 3 clinical trial for its heart medication omecamtiv mecarbil.Here's Why You Should Buy Cytokinetics, Inc.  As Amgen, Inc. (AMGN ... - TCCCytokinetics , Amgen  to Advance Omecamtiv Mecarbil to Phase 3 - StreetInsider.com"
p2
aS"The Cytokinetics, Inc.  Rating Reiterated by HC Wainwright Petro Global News 24 - 18 hours ago Cytokinetics, Inc. 's stock had its buy rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Monday.HC Wainwright Reiterates Buy Rating for Cytokinetics, Inc.  - The Cerbat GemCytokinetics, Inc.  Research Coverage Started at Rodman &amp; Renshaw - BNB Daily "
p3
aS'Cytokinetics Inc. MarketWatch - Dec 21, 2009 Cytokinetics Inc. NASDAQ: CYTK. GO. Set Alerts &middot; Find a Broker &middot; Join TD Ameritrade &middot; Market Index &middot; Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.'
p4
aS'Cytokinetics, Inc.  Reaches $13.65 After 8.00% Up Move, EarthLink ... Wolcott Daily - 12 hours ago The stock of Cytokinetics, Inc.  is a huge mover today! The stock increased 5.00% or $0.65 during the last trading session, reaching $13.65.Cytokinetics Incorporated  Breaks into New 52-Week High on March 15 Session - Equities.comNews Recap: Cytokinetics, Incorporated  , Kennedy-Wilson Holdings ... - NYSE Journal '
p5
aS"JMP Securities Bullish on Cytokinetics, Inc.  Following 2Q Update; Sees ... Smarter Analyst - Aug 1, 2016 In light of Cytokinetics, Inc.'s  second-quarter update, JMP Securities analyst Jason Butler remains bullish for the biotech company's pipeline drug-paved road ahead."
p6
aS"The HC Wainwright Reiterates Buy Rating for Cytokinetics, Inc.  Petro Global News 24 - Mar 13, 2017 Cytokinetics, Inc. 's stock had its buy rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Monday."
p7
aS'Cytokinetics to Present at March Investor Conferences Yahoo Finance - Feb 27, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017  -- Cytokinetics, Inc.  announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences:.Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day - GlobeNewswire '
p8
aS'Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of ... GlobeNewswire  - Dec 1, 2016 SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016  -- Cytokinetics, Inc.  today announced the activation of the first clinical site and the start of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes&nbsp;...Amgen, Cytokinetics Launch Heart Study  - InvestopediaCytokinetics earns $26.7M milestone from Amgen on start of large-scale CV ... - Seeking Alpha'
p9
aS'Cowen Positive on Cytokinetics, Inc.  as Amgen, Inc.  Opts-in to ... Smarter Analyst - Oct 5, 2016 Cowen top analyst Ritu Baral chimes in on Cytokinetics, Inc.  after Amgen, Inc.  recently opted-in to advance their collaborative drug omecamtiv mercarbil, designed to treat people living with heart failure.'
p10
a.